Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

Trastuzumab is a successful rationally designed ERBB2-targeted therapy. However, about half of individuals with ERBB2-overexpressing breast cancer do not respond to trastuzumab-based therapies, owing to various resistance mechanisms. Clinically applicable regimens for overcoming trastuzumab resistan...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zhang, Siyuan, Huang, Wen-Chien, Li, Ping, Guo, Hua, Poh, Say-Bee, Brady, Samuel W, Xiong, Yan, Tseng, Ling-Ming, Li, Shau-Hsuan, Ding, Zhaoxi, Sahin, Aysegul A, Esteva, Francisco J, Hortobagyi, Gabriel N, Yu, Dihua
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3877934/
https://ncbi.nlm.nih.gov/pubmed/21399647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.2309
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados